Bromelain degrades Aβ1-42 monomers and soluble aggregates: An in vitro study in cerebrospinal fluid of alzheimer’s disease patients

Giulia M. Sancesario, Marzia Nuccetelli, Andrea Cerri, Joshua Zegeer, Cinzia Severini, Maria T. Ciotti, Massimo Pieri, Alessandro Martorana, Carlo Caltagirone, Robert Nisticò, Sergio Bernardini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Therapeutic approaches targeting amyloid β42 (Aβ42) oligomers may represent a promising neuroprotective strategy for the prevention and treatment of Alzheimer’s disease (AD). Objective: In this study we evaluated the ability of bromelain, a plant cysteine protease derived from pineapple stems, to interact with synthetic Aβ42 monomers and oligomers. We also examined the ability of bromelain to interfere in vitro with synthetic Aβ42 aggregates in the cerebrospinal fluid (CSF) of Alzheimer’s disease as well as of control patients affected by other neurological diseases. Method: Both synthetic monomers and aggregates of Aβ42 were incubated in CSF with varying concentrations of bromelain. The effects of digestion were evaluated by Western Blot analysis using the specific monoclonal antibody 4G8 to identify the patterns of residual content of Aβ42. We further used rat primary cortical culture neurons (CN) to examine the cytotoxic action of this natural compound. Results: We found that bromelain successfully degraded Aβ42 monomers and low and high molecular weight oligomers. Indeed, when bromelain preparations of 3 and 6 mU were added to the CSF, the residual amount of Aβ42 monomers and oligomers were significantly reduced when compared to the same standard Aβ42 preparations incubated in CSF without bromelain. Moreover, bromelain incubations of 0.1, 0.5, and 1 mU/ml were not toxic to CN, as compared to vehicle treated cells. Conclusion: Overall, these results represent an important insight into the action of bromelain on Aβ42 oligomers, suggesting its potential use in the therapy of AD.

Original languageEnglish
Pages (from-to)628-636
Number of pages9
JournalCurrent Alzheimer Research
Volume15
Issue number7
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Bromelains
Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Aptitude
Ananas
In Vitro Techniques
Neurons
Cysteine Proteases
Poisons
Digestion
Therapeutics
Molecular Weight
Western Blotting
Monoclonal Antibodies

Keywords

  • AD therapy
  • Aggregation
  • Alzheimer’s disease
  • Amyloid β
  • Bromelain
  • Prevention

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Bromelain degrades Aβ1-42 monomers and soluble aggregates : An in vitro study in cerebrospinal fluid of alzheimer’s disease patients. / Sancesario, Giulia M.; Nuccetelli, Marzia; Cerri, Andrea; Zegeer, Joshua; Severini, Cinzia; Ciotti, Maria T.; Pieri, Massimo; Martorana, Alessandro; Caltagirone, Carlo; Nisticò, Robert; Bernardini, Sergio.

In: Current Alzheimer Research, Vol. 15, No. 7, 01.01.2018, p. 628-636.

Research output: Contribution to journalArticle

Sancesario, Giulia M. ; Nuccetelli, Marzia ; Cerri, Andrea ; Zegeer, Joshua ; Severini, Cinzia ; Ciotti, Maria T. ; Pieri, Massimo ; Martorana, Alessandro ; Caltagirone, Carlo ; Nisticò, Robert ; Bernardini, Sergio. / Bromelain degrades Aβ1-42 monomers and soluble aggregates : An in vitro study in cerebrospinal fluid of alzheimer’s disease patients. In: Current Alzheimer Research. 2018 ; Vol. 15, No. 7. pp. 628-636.
@article{91c8a442abd248b884c20079cd8e26eb,
title = "Bromelain degrades Aβ1-42 monomers and soluble aggregates: An in vitro study in cerebrospinal fluid of alzheimer’s disease patients",
abstract = "Background: Therapeutic approaches targeting amyloid β42 (Aβ42) oligomers may represent a promising neuroprotective strategy for the prevention and treatment of Alzheimer’s disease (AD). Objective: In this study we evaluated the ability of bromelain, a plant cysteine protease derived from pineapple stems, to interact with synthetic Aβ42 monomers and oligomers. We also examined the ability of bromelain to interfere in vitro with synthetic Aβ42 aggregates in the cerebrospinal fluid (CSF) of Alzheimer’s disease as well as of control patients affected by other neurological diseases. Method: Both synthetic monomers and aggregates of Aβ42 were incubated in CSF with varying concentrations of bromelain. The effects of digestion were evaluated by Western Blot analysis using the specific monoclonal antibody 4G8 to identify the patterns of residual content of Aβ42. We further used rat primary cortical culture neurons (CN) to examine the cytotoxic action of this natural compound. Results: We found that bromelain successfully degraded Aβ42 monomers and low and high molecular weight oligomers. Indeed, when bromelain preparations of 3 and 6 mU were added to the CSF, the residual amount of Aβ42 monomers and oligomers were significantly reduced when compared to the same standard Aβ42 preparations incubated in CSF without bromelain. Moreover, bromelain incubations of 0.1, 0.5, and 1 mU/ml were not toxic to CN, as compared to vehicle treated cells. Conclusion: Overall, these results represent an important insight into the action of bromelain on Aβ42 oligomers, suggesting its potential use in the therapy of AD.",
keywords = "AD therapy, Aggregation, Alzheimer’s disease, Amyloid β, Bromelain, Prevention",
author = "Sancesario, {Giulia M.} and Marzia Nuccetelli and Andrea Cerri and Joshua Zegeer and Cinzia Severini and Ciotti, {Maria T.} and Massimo Pieri and Alessandro Martorana and Carlo Caltagirone and Robert Nistic{\`o} and Sergio Bernardini",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1567205015666180123124851",
language = "English",
volume = "15",
pages = "628--636",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Bromelain degrades Aβ1-42 monomers and soluble aggregates

T2 - An in vitro study in cerebrospinal fluid of alzheimer’s disease patients

AU - Sancesario, Giulia M.

AU - Nuccetelli, Marzia

AU - Cerri, Andrea

AU - Zegeer, Joshua

AU - Severini, Cinzia

AU - Ciotti, Maria T.

AU - Pieri, Massimo

AU - Martorana, Alessandro

AU - Caltagirone, Carlo

AU - Nisticò, Robert

AU - Bernardini, Sergio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Therapeutic approaches targeting amyloid β42 (Aβ42) oligomers may represent a promising neuroprotective strategy for the prevention and treatment of Alzheimer’s disease (AD). Objective: In this study we evaluated the ability of bromelain, a plant cysteine protease derived from pineapple stems, to interact with synthetic Aβ42 monomers and oligomers. We also examined the ability of bromelain to interfere in vitro with synthetic Aβ42 aggregates in the cerebrospinal fluid (CSF) of Alzheimer’s disease as well as of control patients affected by other neurological diseases. Method: Both synthetic monomers and aggregates of Aβ42 were incubated in CSF with varying concentrations of bromelain. The effects of digestion were evaluated by Western Blot analysis using the specific monoclonal antibody 4G8 to identify the patterns of residual content of Aβ42. We further used rat primary cortical culture neurons (CN) to examine the cytotoxic action of this natural compound. Results: We found that bromelain successfully degraded Aβ42 monomers and low and high molecular weight oligomers. Indeed, when bromelain preparations of 3 and 6 mU were added to the CSF, the residual amount of Aβ42 monomers and oligomers were significantly reduced when compared to the same standard Aβ42 preparations incubated in CSF without bromelain. Moreover, bromelain incubations of 0.1, 0.5, and 1 mU/ml were not toxic to CN, as compared to vehicle treated cells. Conclusion: Overall, these results represent an important insight into the action of bromelain on Aβ42 oligomers, suggesting its potential use in the therapy of AD.

AB - Background: Therapeutic approaches targeting amyloid β42 (Aβ42) oligomers may represent a promising neuroprotective strategy for the prevention and treatment of Alzheimer’s disease (AD). Objective: In this study we evaluated the ability of bromelain, a plant cysteine protease derived from pineapple stems, to interact with synthetic Aβ42 monomers and oligomers. We also examined the ability of bromelain to interfere in vitro with synthetic Aβ42 aggregates in the cerebrospinal fluid (CSF) of Alzheimer’s disease as well as of control patients affected by other neurological diseases. Method: Both synthetic monomers and aggregates of Aβ42 were incubated in CSF with varying concentrations of bromelain. The effects of digestion were evaluated by Western Blot analysis using the specific monoclonal antibody 4G8 to identify the patterns of residual content of Aβ42. We further used rat primary cortical culture neurons (CN) to examine the cytotoxic action of this natural compound. Results: We found that bromelain successfully degraded Aβ42 monomers and low and high molecular weight oligomers. Indeed, when bromelain preparations of 3 and 6 mU were added to the CSF, the residual amount of Aβ42 monomers and oligomers were significantly reduced when compared to the same standard Aβ42 preparations incubated in CSF without bromelain. Moreover, bromelain incubations of 0.1, 0.5, and 1 mU/ml were not toxic to CN, as compared to vehicle treated cells. Conclusion: Overall, these results represent an important insight into the action of bromelain on Aβ42 oligomers, suggesting its potential use in the therapy of AD.

KW - AD therapy

KW - Aggregation

KW - Alzheimer’s disease

KW - Amyloid β

KW - Bromelain

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=85049065379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049065379&partnerID=8YFLogxK

U2 - 10.2174/1567205015666180123124851

DO - 10.2174/1567205015666180123124851

M3 - Article

AN - SCOPUS:85049065379

VL - 15

SP - 628

EP - 636

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 7

ER -